Autologous mesenchymal stem cell therapy (Pharmicell)

自体间充质干细胞疗法（Pharmicell）

Report date: 2023/01/12 15:28:43

Base Information

Drug NameAutologous mesenchymal stem cell therapy (Pharmicell)
Drug Alias NameCellgram-LCHearticellgram®-AMI
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyocardial InfarctionErectile DysfunctionLiver Cirrhosis, Alcoholic
Global Approved IndicationsMyocardial Infarction
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2011/07/01
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFcb-Pharmicell
China Registration ClassN/A

Develop Information

Active CompaniesFcb-PharmicellPharmicell Co Ltd
Inactive CompaniesN/A
Active IndicationsMyocardial InfarctionLiver Cirrhosis, Alcoholic
Inactive IndicationsErectile Dysfunction

Other Information

ATC CodeB05AX
Related LinksN/A